, Dong Hoon Baek
Department of Internal Medicine, Pusan National University School of Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea
© 2026 Korean Society of Gastrointestinal Endoscopy
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflicts of Interest
Dong Hoon Baek is currently serving as a member of the publication committee for Clinical Endoscopy. He was not involved in peer reviewer selection, evaluation, or the decision process for this article. Seung Min Hong has no potential conflicts of interest to declare.
Funding
This work was supported by a clinical research grant from the Pusan National University Hospital in 2025.
Author Contributions
Conceptualization: DHB; Data curation: all authors; Formal analysis: all authors; Investigation: all authors; Methodology: SMH; Project administration: all authors; Resources: SMH; Supervision: DHB; Validation: all authors; Visualization: all authors; Writing–original draft: SMH; Writing–review & editing: all authors.
PEG, polyethylene glycol; ELS, electrolyte lavage solution; IBD, inflammatory bowel disease; G6PD, glucose-6-phosphate dehydrogenase; R.I., renal insufficiency (creatinine clearance <30 mL/min); CHF, congestive heart failure (New York Heart Association class III or IV); SPMC, sodium picosulfate, magnesium oxide, and citric acid; PEG+bisacodyl, polyethylene glycol combined with bisacodyl; PEG+linaclotide, polyethylene glycol combined with linaclotide; Iso, iso-osmotic; hyper, hyperosmotic; dual, stimulant plus osmotic combination.
| Patient factors | Preferred regimen(s) | Agents not recommended |
|---|---|---|
| Age >70 years | PEG-ELS, PEG-ascorbate, OSS, OST | SPMC |
| Chronic kidney disease (eGFR <30 mL/min/1.73 m²) | PEG-ELS | OSS, OST, SPMC |
| Congestive heart failure | PEG-ELS | OSS, OST, SPMC |
| Liver cirrhosis with ascites | PEG-ELS | OSS, OST, SPMC |
| G6PD deficiency | PEG-ELS | PEG with ascorbate |
| History of gout | PEG-ELS, PEG-ascorbate, SPMC | OSS, OST |
| Dysphagia or post-bariatric surgery | PEG-ELS, PEG-ascorbate | OST |
| Pregnancy | PEG-ELS, PEG-ascorbatea), OSSa) | OST, SPMC |
| Active IBD | PEG-ELS, PEG-ascorbate, OSTa) | OSS, SPMC |
PEG-ELS, polyethylene glycol-electrolyte lavage solution; PEG-ascorbate, polyethylene glycol combined with ascorbic acid; OSS, oral sulfate solution; OST, oral sulfate tablet; SPMC, sodium picosulfate with magnesium citrate; eGFR, estimated glomerular filtration rate; G6PD, glucose-6-phosphate dehydrogenase; IBD, inflammatory bowel disease.
a)Agents to use with caution.
| Patient characteristics | Clinical conditions | Social/behavioral features |
|---|---|---|
| Old age (>65 years) | Chronic constipation | Tobacco use |
| Male sex | Diabetes mellitus | Reduced health literacy |
| Obesity with high body mass index (>30 kg/m2) | Hypertension | Low education level |
| Inpatient status | Liver cirrhosis | Low patient activation |
| Prior history of poor preparation | Neurological conditions: stroke, Parkinson disease, dementia | |
| Immobility | ||
| Spinal cord injury | ||
| Previous abdominal and/or pelvic surgery | ||
| Constipating medicine: tricyclic antidepressants, narcotics, opioid use |
| Regimen | Type (mechanism) | Volume | Cleansing efficacy | Key contraindications | Special populations | Benefits | Drawbacks |
|---|---|---|---|---|---|---|---|
| PEG-ELS 4 L | Iso | 4 L | High: reference standard | Bowel obstruction | Older adults, patients who are pregnant, IBD, R.I, ascites | High efficacy; good safety profile | Poor tolerability |
| PEG-ascorbate 2 L | Iso | 3 L (regimen 2 L+water 1 L) | Noninferior to 4 L PEG and non-PEG regimens | Bowel obstruction, G6PD deficiency, phenylketonuria, unstable angina; or acute myocardial infarction, R.I, CHF | Older adults, patients who are pregnant (caution), IBD | Better taste, smaller volume | Risk of hemolysis in G6PD |
| PEG-ascorbate 1 L | Iso | 2 L (regimen 1 L+water 1 L) | Noninferior to 4 L or 2 L PEG | Bowel obstruction, G6PD deficiency, Phenylketonuria, R.I, CHF | Volume-sensitive patients; adequate hydration must be maintained. | High tolerability, convenient | Dehydration and hypernatremia risk in frail or older adults |
| Oral sulfate solution | Hyper | 2.9 L (regimen 0.9 L+water 2 L) | Noninferior to 4 L or 2 L PEG | Bowel obstruction, R.I, CHF, ascites | Young average-risk patients, patients who are pregnant (caution) | Lower volume | Risk of hyperuricemia and dehydration |
| Comparable to SPMC | Hyperuricemia or Gout (caution) | ||||||
| Oral sulfate tablet | Hyper | 3 L (28 tablet+water 3 L) | Noninferior to PEG (any volume); comparable to SPMC | Bowel obstruction, Dysphagia, Post-bariatric surgery | Tablet-tolerant patients | Tablet form, High tolerability, less nausea | Gastric mucosal injury risk |
| R.I, CHF, Ascites | |||||||
| Hyperuricemia or Gout (caution) | |||||||
| SPMC | Dual | 2.34 L (regimen 0.17 L+water 2 L) | Noninferior to 4 L or 2 L PEG | Bowel obstruction, R.I, CHF, ascites | Patients desiring taste/convenience | Excellent taste | Risk of hyponatremia and hypermagnesemia |
| Hypermagnesemia; or rhabdomyolysis. | |||||||
| PEG+bisacodyl | Iso+stimulant | 3 L (regimen 2 L+water 1 L) | Comparable to 4 L PEG | Bowel obstruction, CHF, older adults with vascular disease (caution) | Young/healthy or prior poor prep | More tolerable than 4 L PEG | Rare ischemic colitis |
| Patient factors | Preferred regimen(s) | Agents not recommended |
|---|---|---|
| Age >70 years | PEG-ELS, PEG-ascorbate, OSS, OST | SPMC |
| Chronic kidney disease (eGFR <30 mL/min/1.73 m²) | PEG-ELS | OSS, OST, SPMC |
| Congestive heart failure | PEG-ELS | OSS, OST, SPMC |
| Liver cirrhosis with ascites | PEG-ELS | OSS, OST, SPMC |
| G6PD deficiency | PEG-ELS | PEG with ascorbate |
| History of gout | PEG-ELS, PEG-ascorbate, SPMC | OSS, OST |
| Dysphagia or post-bariatric surgery | PEG-ELS, PEG-ascorbate | OST |
| Pregnancy | PEG-ELS, PEG-ascorbate |
OST, SPMC |
| Active IBD | PEG-ELS, PEG-ascorbate, OST |
OSS, SPMC |
PEG, polyethylene glycol; ELS, electrolyte lavage solution; IBD, inflammatory bowel disease; G6PD, glucose-6-phosphate dehydrogenase; R.I., renal insufficiency (creatinine clearance <30 mL/min); CHF, congestive heart failure (New York Heart Association class III or IV); SPMC, sodium picosulfate, magnesium oxide, and citric acid; PEG+bisacodyl, polyethylene glycol combined with bisacodyl; PEG+linaclotide, polyethylene glycol combined with linaclotide; Iso, iso-osmotic; hyper, hyperosmotic; dual, stimulant plus osmotic combination.
PEG-ELS, polyethylene glycol-electrolyte lavage solution; PEG-ascorbate, polyethylene glycol combined with ascorbic acid; OSS, oral sulfate solution; OST, oral sulfate tablet; SPMC, sodium picosulfate with magnesium citrate; eGFR, estimated glomerular filtration rate; G6PD, glucose-6-phosphate dehydrogenase; IBD, inflammatory bowel disease. Agents to use with caution.
